整合缺陷型重组慢病毒载体构建及HCV重组假型慢病毒颗粒的制备与性状分析

中国生物工程杂志

2013, Vol. 33

Issue (6): 62-67

技术与方法

整合缺陷型重组慢病毒载体构建及HCV重组假型慢病毒颗粒的制备与性状分析

管洁^1,2, 邓瑶¹, 文波¹, 陈红¹, 王文¹, 谭文杰¹

1. 卫生部医学病毒与病毒病重点实验室中国疾病预防控制中心病毒病预防控制所北京 102206;
2. 煤炭总医院中心实验室北京 100028

Development and Characterization of Integration-deficient Lentiviral Vector and HCV Recombinant Pseudotyped Lentiviral Particles

GUAN Jie^1,2, DENG Yao¹, WEN Bo¹, CHEN Hong¹, WANG Wen¹, TAN Wen-Jie¹

1. Key Laboratory of Medical Virology, Ministry of Health; National Institute for Viral Disease Control and Prevention, China CDC, Beijing 102206, China;
2. Central Laboratory, Meitan General Hospital, Beijing 100028, China

全文: PDF(737 KB) HTML

摘要：

为提高慢病毒载体应用的安全性及改进HCV新型颗粒疫苗的制备,首先对传统的慢病毒三质粒系统进行改造:将包装质粒pHR’CMVΔR8.2改造成整合缺陷型的包装质粒pHR’CMVΔR8.2D64E,并在体外感染实验验证其整合缺陷性;将转移质粒中的报告基因GFP替换成HCV的NS3基因,选用表达3种亚型(1a、1b、2a)HCV包膜E1E2的包膜质粒,用改造后的三质粒系统制备了3种亚型(1a,1b,2a)的假型丙型肝炎病毒(HCV)整合缺陷型慢病毒颗粒,并用Western blot方法确定了颗粒上包膜蛋白的表达,通过电镜可观察到浓缩后的HCV慢病毒颗粒结构,HCV慢病毒颗粒感染Huh7细胞后可观察到转基因NS3的表达。为安全高效的慢病毒载体的应用及HCV假型颗粒疫苗研发提供了新的技术路线。

关键词： 整合缺陷; 慢病毒载体; 丙型肝炎病毒; 假型颗粒

Abstract:

In order to improve the safety of lentiviral vector and improve the preparation of novel hepatitis C virus (HCV) particle vaccine,the traditional three plasmid-base lentiviral system was modificated: the packaging plasmid pHR’CMV Δ R8.2 was transformed into the integration-deficient packaging plasmid pCMVΔR8.2D64E, and confirmed the integration-defective properties in vitro. The reporter gene (GFP) in transfer plasmid was replaced by the HCV non-structural gene NS3. HCV envelope plasmid with different subtypes (from three representative subtypes 1a or 1b or 2a) combined with the above two modified lentiviral plasmids were cotransfected 293FT cells. HCV integration-defective pseudotyped lentiviral particle (IDLVpp) vaccines carrying HCV NS3 were packaged. The HCV IDLVpp were identified by Western blot, and the particle structure was observed by electron microscope. The expression of transgenic HCV NS3 in Huh7 cells infected by HCV IDLVpp was also observed. So a scientific and experimental basis for novel effective HCV vaccines development and applications of HCV IDLVpp vaccines was provided.

Key words: Integration-defective Lentiviral vector Hepatitis C virus Pseudotyped lentiviral particles

收稿日期: 2013-01-29 出版日期: 2013-06-25

ZTFLH:

R375.1

基金资助:

十一五传染病重大专项(2009ZX10004-705,-715)资助项目

通讯作者: 谭文杰 E-mail: tanwj28@yahoo.com

	服务
	把本文推荐给朋友
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	管洁
	邓瑶
	文波
	陈红
	王文
	谭文杰

引用本文:

管洁, 邓瑶, 文波, 陈红, 王文, 谭文杰. 整合缺陷型重组慢病毒载体构建及HCV重组假型慢病毒颗粒的制备与性状分析[J]. 中国生物工程杂志, 2013, 33(6): 62-67.

GUAN Jie, DENG Yao, WEN Bo, CHEN Hong, WANG Wen, TAN Wen-Jie. Development and Characterization of Integration-deficient Lentiviral Vector and HCV Recombinant Pseudotyped Lentiviral Particles. China Biotechnology, 2013, 33(6): 62-67.

链接本文:

https://manu60.magtech.com.cn/biotech/CN/ 或 https://manu60.magtech.com.cn/biotech/CN/Y2013/V33/I6/62

[1] Zufferey R, Dull T, Mandel R J, et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol,1998,72:9873-9880.
[2] Naldini L, Blomer U, Gallay P, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science,1996,272:263-267.
[3] Kootstra N A, Verma I M. Gene therapy with viral vectors. Annu Rev Pharmacol Toxicol, 2003,43:413-439.
[4] Blomer U, Naldini L, Kafri T, et al. Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector. J Virol,1997,71:6641-6649.
[5] Abordo-Adesida E, Follenzi A, Barcia C, et al. Stability of lentiviral vector-mediated transgene expression in the brain in the presence of systemic anti-vector immune responses. Hum Gene Ther, 2005, 16:741-751.
[6] Janka M, Marinee K L, Thierry V D. Recent advances in lentiviral vector development and applications.Mol Ther,2010,18(3):477-490.
[7] 张珂,谭文杰,邓瑶,等.三种丙型肝炎包膜感染性假病毒颗粒的制备及初步应用研究.病毒学报,2008, 24(4):287-294. Zhang K, Tan W J, Deng Y, et al. Development of infectious pseudo-particle harboring three subtypes hepatitis C virus giycoproteins and their application in neutralization assays. Chinese Journal of Virology, 2008, 24(4):287-294.
[8] Leavitt A D, Shiue L, Varmus H E. Site-directed mutagenesis of HIV-1 integrase demonstrates differential effects on integrase functions in vitro. J Bio Chem, 1993,268:2113-2119.
[9] Engelman A. In vivo analysis of retroviral integrase structure and function. Adv Virus Res,1999 52:411-426.
[10] 管洁,王秀平,邓瑶,等。含分泌型萤光素酶和绿色荧光蛋白双报告基因的慢病毒载体的制备与表达分析.生物技术通讯,2011,22(2):199-202. Guan J, Wang X P, Deng Y, et al. Development and expression analysis of recombinant lentiviral vectors containing gaussia luciferase and green fluorescent protein dual report gene. Letters In Biotechnology, 2011,22(2):199-202.
[11] Murphy D, Chamberland J, Dandavino R, et al. A new genotype of hepatitis C virus originating from central Africa. Hepatology, 2007,46:267-276.
[12] Rehermann B,Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol,2005,5(3):215-229.
[13] Houghton M, Abrignani S. Prospects for a vaccine against the hepatitis C virus. N Engl J Med,1998,339:1485-1492.
[14] Lindenbach B D, Rice C M. Unravelling hepatitis C virus replication from genome to function. Nature, 2005, 436(7053):933-938.
[15] Bowen D G, Walker C M. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature, 2005, 436(7053):946-952.
[16] Diepolder H M, Zachoval R, Hoffmann R M, et al. Possible mechanism involving T-lymphocyte response to nonstructural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet,1995,346:1006-1007.

[1]	赵晓煜,徐祺玲,赵晓东,安云飞. 基因治疗慢病毒载体的转导增强策略^*[J]. 中国生物工程杂志, 2021, 41(8): 52-58.
[2]	韩亚丽,杨冠恒,陈雁雯,龚秀丽,张敬之. 表达β-珠蛋白基因的安全性慢病毒载体的优化 ^*[J]. 中国生物工程杂志, 2018, 38(7): 50-57.
[3]	高越, 檀硕, 任兆瑞, 张敬之. 原位染色检测慢病毒载体转录通读方法的建立[J]. 中国生物工程杂志, 2015, 35(5): 55-60.
[4]	李玉强, 朱志图, 王巍, 李谌, 徐娜, 王钰, 李男, 孙宏治. *RNA干扰NUP88基因对人乳腺癌MCF-7细胞生长及侵袭力的影响*[J]. 中国生物工程杂志, 2014, 34(9): 31-39.
[5]	王鑫, 陈玲, 孙飞, 陆航. RNAi沉默CXCR7对人结肠癌细胞SW620特异性靶向抑制的实验研究[J]. 中国生物工程杂志, 2014, 34(2): 14-20.
[6]	李袁飞, 赵和平, 刘静, 朱国强, 张革红, 贾军梅, 杨文慧. 在结肠癌细胞中RNA干扰TGFBR2慢病毒载体的构建及其功能的初步研究[J]. 中国生物工程杂志, 2013, 33(5): 28-34.
[7]	燕海峰, 易康乐, TREFIL P, 胡雄贵, 邓缘, 朱立军. 慢病毒载体导入种蛋内鸡胚技术研究[J]. 中国生物工程杂志, 2012, 32(12): 73-79.
[8]	李建彬, 米志强, 安小平, 谭莉, 陈斌, 王晓娜, 范华昊, 张文慧, 张博, 方祥, 童贻刚. shRNA随机文库结合TK自杀基因筛选靶向HIV-1LTR相关宿主因子[J]. 中国生物工程杂志, 2012, 32(09): 48-54.
[9]	石永乾, 何文腾, 周洋, 焦明霞, 解炳腾, 胡魁, 孔庆然, 刘忠华. 慢病毒载体介导的绿色荧光蛋白转基因标记法研究猪嵌合体制作[J]. 中国生物工程杂志, 2012, 32(08): 68-74.
[10]	钟艳平, 林若芸, 黎丹戎, 胡晓霞, 王琪, 李力. hTERT重组第三代慢病毒载体的构建及其病毒包装鉴定[J]. 中国生物工程杂志, 2011, 31(9): 21-27.
[11]	陈斌, 李建彬, 米志强, 安小平, 李存, 刘大斌, 姜焕焕, 王娟, 黄芬, 张宝中, 范华昊, 何后军, 童贻刚. 利用移码突变和终止密码子提高下游目的基因的表达水平[J]. 中国生物工程杂志, 2011, 31(8): 92-96.
[12]	王丽娴, 王东阳, 李星, 夏海滨. 携带三种报告基因慢病毒载体的构建及其实验研究[J]. 中国生物工程杂志, 2011, 31(12): 86-92.
[13]	史文芳, 冯悦, 魏大巧, 夏雪山. 丙型肝炎病毒靶向药物及抗病毒药物筛选[J]. 中国生物工程杂志, 2011, 31(11): 95-101.
[14]	胡巍刘文凌世淦. HCV丝氨酸蛋白酶小分子底物构建及GST融合表达[J]. 中国生物工程杂志, 2010, 30(03): 22-26.
[15]	张文军,宁容,张欣,李红枝. HCV特异性M1GS核酶的构建及体外切割活性研究[J]. 中国生物工程杂志, 2008, 28(9): 99-103.

Viewed

Full text

Abstract

Cited

Shared

Discussed